Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Description: Agonists of the vitamin D receptor are used to suppress parathyroid hormone (PTH) synthesis and secretion in the treatment of hyperparathyroidism associated with renal failure. 22-Oxacalcitriol is an analog of calcitriol that, like calcitriol, is a receptor-active form of vitamin D3 which effectively blocks PTH synthesis. First reported to avoid hypercalcemia, an undesirable side effect of calcitriol, prolonged treatment with 22-oxalcalcitriol can be calcemic in humans. Analogs of calcitriol, including 22-oxacalcitriol, inhibit human keratinocyte proliferation while inducing differentiation and is beneficial in treating psoriasis. 22-Oxacalcitriol also blocks the proliferation while inducing differentiation and apoptosis of certain tumor cells.
22-Oxacalcitriol is supplied as a crystalline solid. A stock solution may be made by dissolving the 22-oxacalcitriol in the solvent of choice. 22-Oxacalcitriol is soluble in ethanol, which should be purged with an inert gas. The solubility of 22-oxacalcitriol in ethanol is approximately 1 mg/ml. It is slightly soluble in acetone, chloroform, and DMSO and insoluble in water.
Brown, A.J., Dusso, A.S., and Slatopolsky, E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol. Dial. Transplant. 17, 10-19 (2002).
Brown, A.J., Ritter, C.R., Finch, J.L., et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J. Clin. Invest. 84, 728-732 (1989).
Akizawa, T., Suzuki, M., Akiba, T., et al. Long-term effect of 1,25-dihydroxy-22-oxavitamin D3 on secondary hyperparathyroidism in haemodialysis patients. One-year administration study. Nephrol. Dial. Transplant. 17, 28-36 (2002).
Takahashi, H., Ibe, M., Kinouchi, M., et al. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J. Dermatol. Sci. 31(1), 21-28 (2003).
Okubo, Y., Natsume, S., Usui, K., et al. Combination therapy using maxacalcitol and corticosteroid lotions preliminary to monotherapy with maxacalcitol lotion for scalp psoriasis. J. Dermatolog. Treat. (2012).